MX2013006353A - Metodos y composiciones utiles para promover el sueño en animales. - Google Patents

Metodos y composiciones utiles para promover el sueño en animales.

Info

Publication number
MX2013006353A
MX2013006353A MX2013006353A MX2013006353A MX2013006353A MX 2013006353 A MX2013006353 A MX 2013006353A MX 2013006353 A MX2013006353 A MX 2013006353A MX 2013006353 A MX2013006353 A MX 2013006353A MX 2013006353 A MX2013006353 A MX 2013006353A
Authority
MX
Mexico
Prior art keywords
animal
methods
animals
compositions useful
sleep
Prior art date
Application number
MX2013006353A
Other languages
English (en)
Inventor
Brian Michael Zanghi
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013006353A publication Critical patent/MX2013006353A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se proporcionan métodos y composiciones para promover el sueño en un animal. En un aspecto general, una cantidad promotora del sueño de astaxantina y una cantidad promotora del sueño de melatonina se administran juntas a un animal. La astaxantina se puede administrar en una cantidad que varíe de aproximadamente 0.1 a aproximadamente 60 mg/kg/peso corporal del animal. La melatonina se puede administrar en una cantidad que varíe de aproximadamente 0.1 a aproximadamente 40 mg/kg/peso corporal del animal. El método puede comprender además administrar conjuntamente una cantidad promotora del sueño de zinc al animal. El zinc puede ser administrado en una cantidad que varíe de aproximadamente 10 a aproximadamente 100 mg/kg/de peso corporal del animal.
MX2013006353A 2010-12-07 2011-11-14 Metodos y composiciones utiles para promover el sueño en animales. MX2013006353A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45918110P 2010-12-07 2010-12-07
PCT/US2011/060597 WO2012078317A1 (en) 2010-12-07 2011-11-14 Methods and compositions useful for promoting sleep in animals

Publications (1)

Publication Number Publication Date
MX2013006353A true MX2013006353A (es) 2013-08-26

Family

ID=46207452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006353A MX2013006353A (es) 2010-12-07 2011-11-14 Metodos y composiciones utiles para promover el sueño en animales.

Country Status (11)

Country Link
US (1) US20130273176A1 (es)
EP (1) EP2648513A4 (es)
JP (1) JP2014505031A (es)
CN (1) CN103228139A (es)
AU (1) AU2011338846B2 (es)
BR (1) BR112013016554A2 (es)
CA (1) CA2819595A1 (es)
MX (1) MX2013006353A (es)
RU (1) RU2594876C2 (es)
WO (1) WO2012078317A1 (es)
ZA (1) ZA201305086B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014054651A1 (ja) * 2012-10-03 2016-08-25 富士フイルム株式会社 睡眠改善剤、ノンレム睡眠時間増加剤及び鎮静剤
JPWO2015099102A1 (ja) * 2013-12-27 2017-03-23 富士フイルム株式会社 亜鉛含有睡眠改善剤、ノンレム睡眠時間増加剤及び鎮静剤
CN110882245A (zh) * 2019-12-16 2020-03-17 厦门市健康医疗大数据中心(厦门市医药研究所) 一种改善睡眠的组合物及其用途
ES2837877A1 (es) * 2019-12-31 2021-07-01 Laboratorios Vinas S A Composicion galenica, para uso oral, liquida, que comprende melatonina y una sal de zinc y metodo y uso correspondientes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951842B1 (en) * 1999-01-20 2002-12-04 N.V. Nutricia Infant formula
US7211280B1 (en) * 1999-09-09 2007-05-01 Nestec S.A. Condition of elderly pets
WO2001087291A1 (fr) * 2000-05-16 2001-11-22 Suntory Limited Compositions permettant de regulariser le rythme circadien
US20020120001A1 (en) * 2000-10-13 2002-08-29 Ashni Naturaceuticals, Inc. Compositions containing tryptamines, cartenoids and tocotrienols and having synergistic antioxidant effect
US6974841B1 (en) * 2002-09-27 2005-12-13 Rapisarda Family Irrevocable Trust Pet anti-aging wellness supplement
US20050249785A1 (en) * 2003-08-13 2005-11-10 Gordon John G Use of melatonin-containing oral supplement with animals
WO2005058064A1 (ja) * 2003-12-19 2005-06-30 Menicon Co., Ltd. アスタキサンチン配合ペット用食物
JP4951162B2 (ja) * 2004-04-06 2012-06-13 太陽化学株式会社 睡眠改善用組成物
CN103349184A (zh) * 2006-04-04 2013-10-16 希尔氏宠物营养品公司 用于增加动物的抗氧化状态的组合物和方法
CA2773523A1 (en) * 2009-09-11 2011-03-17 Nestec S.A. Compositions and methods for enhancing cognitive and related functions in animals

Also Published As

Publication number Publication date
AU2011338846A1 (en) 2013-06-13
RU2013131098A (ru) 2015-01-20
CA2819595A1 (en) 2012-06-14
WO2012078317A1 (en) 2012-06-14
CN103228139A (zh) 2013-07-31
US20130273176A1 (en) 2013-10-17
EP2648513A1 (en) 2013-10-16
AU2011338846B2 (en) 2016-04-14
ZA201305086B (en) 2014-12-23
JP2014505031A (ja) 2014-02-27
EP2648513A4 (en) 2014-04-30
RU2594876C2 (ru) 2016-08-20
BR112013016554A2 (pt) 2016-07-12

Similar Documents

Publication Publication Date Title
NZ595987A (en) A novel formulation of diclofenac
WO2012017166A3 (fr) Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
PH12016500746A1 (en) A novel formulation of meloxicam
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
NZ706990A (en) A veterinary method of alleviating noise aversion
MX2013006353A (es) Metodos y composiciones utiles para promover el sueño en animales.
MX2013013098A (es) Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
NZ595798A (en) Ectoparasiticidal methods and formulations
MY160509A (en) Adiponectin production accelerating composition
MD3422G2 (ro) Procedeu de profilaxie şi tratament al knemidocoptozei galinaceelor
WO2012134590A3 (en) Calcium supplement
WO2013052433A3 (en) Methods and compositions for reducing food intake and body weight gain in animals
RU2011134925A (ru) Способ повышения радиосенсибилизации тканей животных
MX2013012990A (es) Metodos y composiciones para preservar la masa corporal magra durante la perdida de peso.
RU2011134662A (ru) Способ предотвращения развития стрессовых реакций в организме животных
MX360787B (es) Metodos para reducir neurodegeneracion.
TH143143A (th) วิธีและองค์ประกอบที่มีประโยชน์สำหรับชักนำให้สัตว์นอนหลับ
UA95405C2 (uk) Спосіб підвищення функціональної здатності печінки курчат-бройлерів при інтенсивному їх вирощуванні
UA67215U (ru) Способ создания модели отравления крыс наночастицами свинца
UA42066U (ru) Способ лечения телят при эймериозно-стронгилоидозной инвазии
UA55533U (ru) Ажених тваринспособ профилактики нарушений морфофункциональных свойств тканей печени в онтогенезе потомков гамма-облученных и подвергнутых стрессу животных
RU2010146367A (ru) Способ моделирования экспериментального амилоидоза у животных
UA91458U (uk) Спосіб корекції активності ферментів крові курчат за еймеріозної інвазії